Literature DB >> 1543208

Subtle glucocorticoid excess in patients with adrenal incidentaloma.

H N Rosen1, S L Swartz.   

Abstract

Incidentally discovered adrenal tumors (incidentalomas) are fairly common since the advent of noninvasive methods of imaging the abdomen. Patients with incidentaloma usually undergo screening for overproduction of glucocorticoids by measurement of basal steroid excretion. We describe an asymptomatic patient with an incidentaloma with normal basal steroid excretion whose only manifestation of subtle steroid overproduction was the failure of steroid excretion to be suppressed normally with dexamethasone. It appears tht the more careful the search for subtle evidence of steroid overproduction in patients with incidentaloma, the more common the finding; perhaps up to 50% of patients with incidentaloma have some subtle steroid overproduction. We review the literature on this subject, and evaluate the various possible approaches of how intensively to study steroid dynamics in patients with incidentaloma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1543208     DOI: 10.1016/0002-9343(92)90115-r

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

1.  Adrenal incidentalomas: incidental in detection, not significance.

Authors:  T C Ooi
Journal:  CMAJ       Date:  1997-10-01       Impact factor: 8.262

Review 2.  The clinical evaluation of silent adrenal masses.

Authors:  B Ambrosi; E Passini; T Re; L Barbetta
Journal:  J Endocrinol Invest       Date:  1997-02       Impact factor: 4.256

3.  Utility of plasma dehydroepiandrosterone sulphate determination in adrenal incidentalomas.

Authors:  G P Bernini; G F Argenio; M S Vivaldi; A Moretti; P Miccoli; P Iacconi; A Magagna; A Salvetti
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

Review 4.  Adrenal incidentaloma: subclinical Cushing's syndrome.

Authors:  J Newell-Price; A Grossman
Journal:  Postgrad Med J       Date:  1996-04       Impact factor: 2.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.